Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 14 min 16 sec ago

Straub Medical AG obtains approval for Rotarex(R)S and Aspirex(R)S endovascular catheters in China

Thu, 01/08/2015 - 13:32
Chinese FDA approves Straub Endovascular System Wangs, Switzerland, (Healthcare Sales & Marketing Network) - Straub Medical AG announced today that the Chinese FDA has approved the Straub Endovascular System with its Rotarex®S and Aspirex®S rota...
Devices, Interventional, Regulatory
Straub Medical AG, Straub Endovascular, RotarexS, AspirexS, rotational catheters

Vascular Dynamics Inc. Secures $16.85 Million Series B Financing

Thu, 01/08/2015 - 13:17
The Funding Will Be Used to Advance the Company's Program for the Treatment of Resistant Hypertension MOUNTAIN VIEW, CA--(Healthcare Sales & Marketing Network) - Vascular Dynamics Inc. (VDI) a medical device company providing minimally invasive solution...
Devices, Venture Capital
Vascular Dynamics, resistant hypertension, MobiusHD, CALM-FIM

Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors

Thu, 01/08/2015 - 13:06
Identifies Up to 44 Percent More Eligible Patients Than Conventional BRCA Tests SALT LAKE CITY and ZURICH, Jan. 8, 2015 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (MYGN) today announced the Company has obtained CE Marking in Euro...
Diagnostics, Oncology, Regulatory
Myriad Genetics, BRACAnalysis CDx, BRCA1, BRCA2, Lynparza, PARP

Philips receives FDA 510(k) clearance for its latest Avalon CL Fetal Monitoring solution

Wed, 01/07/2015 - 13:14
Advanced cableless solution detects fetal heart rate and maternal pulse allowing beneficial freedom of movement during labor ANDOVER, Mass., Jan. 7, 2015 -- (Healthcare Sales & Marketing Network) -- Royal Philips (NYSE: PHG AEX: PHIA) today announced ...
Devices, Monitoring, FDA
Royal Philips, Avalon CL, Fetal Monitoring

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin(TM) Platform for Cancer Therapeutics

Wed, 01/07/2015 - 13:07
Company’s Technology and Expertise in Cancer R&D Evolve to Create New Class of Miniaturized Biologic Drug Conjugates (mBDCs) Encapsulated in Nanoparticles WATERTOWN, Mass.--(Healthcare Sales & Marketing Network)--Blend Therapeutics, Inc., a biopharmaceu...
Biopharmaceuticals, Oncology, Venture Capital
Blend Therapeutics, Pentarin , miniaturized biologic drug conjugates

AVEO Announces Executive Transition and Corporate Restructuring

Wed, 01/07/2015 - 13:01
Michael P. Bailey Named President and Chief Executive Officer; Tuan Ha-Ngoc Named Chairman of the Board Company to Eliminate Internal Research Function to Align Corporate Resources with the Company’s Future Strategic Plans CAMBRIDGE, Mass.--(Healthc...
Biopharmaceuticals, Oncology, Personnel
AVEO Oncology

Mundipharma receives positive European Commission decision on Targin(R) (oxycodone/naloxone) for the treatment of Restless Legs Syndrome1

Wed, 01/07/2015 - 12:53
CAMBRIDGE, England--(Healthcare Sales & Marketing Network)--Mundipharma today announced that Targin® (Targinact®, Targiniq®), a fixed combination of prolonged-release oxycodone/naloxone, has received a positive European Commission decision for ...
Biopharmaceuticals, Regulatory
Mundipharma, Targin, Targinact, Targiniq, restless legs syndrome

CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments

Tue, 01/06/2015 - 13:05
Financing will help support advancement of Probody therapeutics towards the clinic SOUTH SAN FRANCISCO, Calif., Jan. 6, 2015 -- (Healthcare Sales & Marketing Network) -- CytomX, a biotechnology company developing Probody™ therapeutics for the treatment...
Biopharmaceuticals, Oncology, Venture Capital
CytomX Therapeutics, Probody

Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics

Tue, 01/06/2015 - 13:00
Isis-owned Subsidiary Launched to Conduct Development and Commercialization of Isis' Lipid Franchise Drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2015 -- (Healthcare Sales & Marketing Network) -- Isis Pharmaceuticals, Inc. (ISIS) announced toda...
Biopharmaceuticals, Personnel
Isis Pharmaceuticals, Akcea Therapeutics

Cohera Medical, Inc.(R) Receives PMA Approvable Letter from U.S. FDA for TissuGlu(R) Surgical Adhesive

Tue, 01/06/2015 - 12:53
Cohera CEO to present on latest Company updates at 33rd Annual J.P. Morgan Healthcare Conference PITTSBURGH, Jan. 6, 2015 -- (Healthcare Sales & Marketing Network) -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical a...
Devices, FDA
Cohera Medical, surgical adhesive, TissuGlu

CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)

Tue, 01/06/2015 - 12:46
Aldoxorubicin Shows a Complete Response, Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients Novel Albumin-Binding Drug Candidate Appears to Allow Doxorubicin to Cross the Tumor's Blood-Brain Barrier in Humans LOS ANGELE...
Biopharmaceuticals, Oncology
CytRx, aldoxorubicin, glioblastoma multiforme, brain cancer

Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer

Mon, 01/05/2015 - 23:56
CORAL GABLES, Fla., Jan. 5, 2015 -- (Healthcare Sales & Marketing Network) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people wi...
Biopharmaceuticals, Personnel
Catalyst Pharmaceutical, Firdapse

GlySens Incorporated Secures $12M Series C Investment

Mon, 01/05/2015 - 23:51
Proceeds dedicated to advanced product commercialization steps SAN DIEGO, Jan. 5, 2015 -- (Healthcare Sales & Marketing Network) -- GlySens Incorporated announced today that it has closed a $12 million dollar Series C investment round, which included p...
Devices, Endocrinology, Venture Capital
GlySens, continuous glucose monitoring system

Aduro Biotech Closes $51.4 Million Series D Financing

Mon, 01/05/2015 - 13:12
Investment for Expansion of Research and Clinical Development of Aduro’s Immuno-Oncology Technology Platforms BERKELEY, Calif.--(Healthcare Sales & Marketing Network)--Aduro Biotech, Inc., a clinical-stage immuno-oncology company, today announced the cl...
Biopharmaceuticals, Oncology, Venture Capital
Aduro Biotech

Stereotaxis Receives FDA Clearance of Vdrive(R) With V-CAS(TM) System Along With Regulatory Approval of Odyssey(R) System in Japan

Mon, 01/05/2015 - 13:05
ST. LOUIS, Jan. 5, 2015 -- (Healthcare Sales & Marketing Network) -- Stereotaxis, Inc. (STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration (FDA) for its Vdrive(R) with V-CAS(TM) Catheter Advancement System in th...
Devices, Cardiology, Regulatory
Stereotaxis, Vdrive , V-CAS , Catheter Advancement System

CardioFocus partners with Japan Lifeline for distribution of the HeartLight Laser Balloon to treat Atrial Fibrillation

Mon, 01/05/2015 - 12:58
Massachusetts company taps Japan EP market leader to introduce proprietary technology MARLBOROUGH, Mass., Jan. 5, 2015 -- (Healthcare Sales & Marketing Network) -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the t...
Devices, Cardiology, Distribution
CardioFocus, Japan Lifeline Co, HeartLight, Endoscopic Ablation

Exact Sciences: Additional Update on CMS Reimbursement for Cologuard(R)

Fri, 01/02/2015 - 12:45
MADISON, Wis.--(Healthcare Sales & Marketing Network)--Exact Sciences Corp. (EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published an updated 2015 Clinical Laboratory Fee Schedule, which includes reimbursement for Ex...
Diagnostics, Reimbursement
Exact Sciences, Cologuard, colon cancer

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong